Index Changes Announcement: Elanco Animal Health Inc. will replace Sarepta Therapeutics Inc. in the S&P MidCap 400, while Sarepta will take Brookline Bancorp's place in the S&P SmallCap 600, effective September 2, 2025.
Acquisition Details: Berkshire Hills Bancorp is acquiring Brookline Bancorp, and after the merger, it will continue to be part of the S&P SmallCap 600 under a new name, Beacon Financial Corp.
Effective Date and Actions: The changes will occur prior to the opening of trading on September 2, 2025, with specific additions and deletions listed for both indices.
About S&P Dow Jones Indices: S&P Dow Jones Indices is a leading provider of index-based data and research, managing some of the most recognized financial market indicators globally.
SRPT
$21.55+Infinity%1D
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 18.35 USD with a low forecast of 5.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 18.35 USD with a low forecast of 5.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
12 Hold
5 Sell
Hold
Current: 21.530
Low
5.00
Averages
18.35
High
37.00
Current: 21.530
Low
5.00
Averages
18.35
High
37.00
Citizens
Outperform
maintain
$87 -> $120
2025-12-12
New
Reason
Citizens
Price Target
$87 -> $120
2025-12-12
New
maintain
Outperform
Reason
Citizens raised the firm's price target on Structure Therapeutics to $120 from $87 and keeps an Outperform rating on the shares. The Phase 2b data for aleniglipron fundamentally derisk the small molecule GLP agonist, and the firm is not losing the forest through the trees, the analyst tells investors in a research note. There could be ongoing debate on aleniglipron's tolerability, but there is solid evidence to support an improved Phase 3 profile, the firm adds.
Wedbush
NULL -> Outperform
initiated
$32
2025-12-09
Reason
Wedbush
Price Target
$32
2025-12-09
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Sarepta with an Outperform rating and $32 price target.
Wedbush
Outperform
initiated
$32
2025-12-09
Reason
Wedbush
Price Target
$32
2025-12-09
initiated
Outperform
Reason
As previously reported, Wedbush initiated coverage of Sarepta with an Outperform rating and $32 price target. The firm sees the early summer selloff due to Elevidys patient deaths as overdone, and even after the subsequent recovery following the Food and Drug Administration's quick reversal for Elevidys to remain available to ambulatory patients, Wedbush sees further upside from potential re-approval in non-ambulatory patients as well. On exon-skipping products that have stably generated close to $1B in annual sales, despite the recent negative ESSENCE study data and emerging competition, the firm projects continued patient uptake based on a high compliance rate that Sarepta has reported, comprehensive real world data supporting clinical benefit, and favorable key opinion leader feedback.
Bernstein
Market Perform
maintain
$18 -> $20
2025-11-25
Reason
Bernstein
Price Target
$18 -> $20
2025-11-25
maintain
Market Perform
Reason
Bernstein raised the firm's price target on Sarepta to $20 from $18 and keeps a Market Perform rating on the shares. The firm cites higher estimates for Elevidys, partially offset by a slightly lower multiple reflecting greater uncertainty on PMO durability post-ESSENCE.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
